A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

NCT06809179 | Recruiting Phase 2 FDA Drug

• 1 other identifier: PH94B-CL036
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 9

Brief Summary

This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PH94B-CL036 and choose to enter the distinct open-label extension phase of the study.

Conditions

Social Anxiety Disorder

Keywords

Fasedienol; PH94B; social anxiety disorder; social anxiety; SAD; pherine; pherine nasal spray; acute treatment; anxiolytic; mental health; performance anxiety; anxiety nasal spray; anxiety treatment; public speaking anxiety; social phobia; phobic disorders; mental disorder; speech task

Outcome Measures

Primary Outcomes (1)

• Subjective Units of Distress Scale (SUDS)

  The SUDS is a patient self-rated acute measurement scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety at all and 100=highest distress or anxiety ever felt.

  7 days (Visit 2 to Visit 3)

Secondary Outcomes (2)

• Global Impression Scale of Improvement (CGI-I)

  7 days (Visit 2 to Visit 3)

• Patient Global Impression of Change (PGI-C)

  7 days (Visit 2 to Visit 3)

Study Arms (3)

Fasedienol Nasal Spray (single dose)

EXPERIMENTAL

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.

Drug: Fasedienol Nasal Spray - Placebo Nasal Spray

Fasedienol Nasal Spray (repeat dose)

EXPERIMENTAL

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.

Drug: Fasedienol Nasal Spray - Fasedienol Nasal Spray

Placebo Nasal Spray

EXPERIMENTAL

Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.

Drug: Placebo Nasal Spray - Placebo Nasal Spray

Interventions

Fasedienol Nasal Spray - Placebo Nasal Spray DRUG

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.

Fasedienol Nasal Spray (single dose)

Placebo Nasal Spray - Placebo Nasal Spray DRUG

Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.

Placebo Nasal Spray

Fasedienol Nasal Spray - Fasedienol Nasal Spray DRUG

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.

Fasedienol Nasal Spray (repeat dose)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent provided prior to conducting any study-specific assessment.
• Male and female adults, 18 through 65 years of age, inclusive.
• Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
• Clinician-rated Liebowitz Social Anxiety Score (LSAS) total score ≥70 at Screening (Visit 1).
• Clinician-rated Hamilton Depression Rating Scale (HAM-D) (17-items) total score \<16.
• Female subjects of childbearing potential must be able to commit to the consistent and correct use of an effective method of birth control throughout the study
• Subjects must have normal olfactory function

You may not qualify if:

• Any history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.
• Any other current principal or personality disorder (previously known as Axis I or Axis II disorders), except for specific phobias or generalized anxiety disorder, provided that these are not the primary diagnosis.
• Subjects who meet criteria for moderate or severe alcohol use disorder within the 1 year prior to study entry, or any use of illicit substances or tetrahydrocannabinol ("THC") within 2 months prior to study entry.
• In the opinion of the investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or the subject is considered to be an imminent danger to themself or others.
• Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, total anosmia, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.
• Two or more documented failed adequate treatment trials with a registered medication approved for SAD.
• Currently receiving cognitive-behavioral therapy (CBT), exposure therapy, or acceptance and commitment therapy.
• Subjects taking psychotropic medications within 30 days before Visit 2.
• Use of any over-the-counter product, prescription product, off-label treatment, cannabidiol ("CBD"), or herbal preparation for treatment of the symptoms of anxiety or social anxiety within 30 days before Visit 2.
• Prior participation in a clinical trial involving fasedienol.
• Participation in any other clinical trial within the last 30 days or during the course of the current trial.
• Subjects with a positive urine drug screen.
• Women who have a positive urine pregnancy test.
• Women who are currently breastfeeding are not eligible unless they are willing to stop breastfeeding for the duration of the study.
• Subjects who have tested positive and/or have exhibited symptoms consistent with SARS-CoV-2 infection during the 4 weeks prior to Screening (Visit 1).

Sponsors & Collaborators

• VistaGen Therapeutics, Inc.: lead

Study Sites (9)

Vistagen Clinical Site

Sherman Oaks, California, 91403, United States

RECRUITING

Vistagen Clinical Site

Walnut Creek, California, 94596, United States

RECRUITING

Vistagen Clinical Site

Largo, Florida, 33777, United States

RECRUITING

Vistagen Clinical Site

Saint Charles, Missouri, 63304, United States

RECRUITING

Vistagen Clinical Site

Toms River, New Jersey, 08755, United States

RECRUITING

Vistagen Clinical Site

Cary, North Carolina, 27511, United States

RECRUITING

Vistagen Clinical Site

Cleveland, Ohio, 44130, United States

TERMINATED

Vistagen Clinical Site

Plymouth Meeting, Pennsylvania, 19462, United States

RECRUITING

Vistagen Clinical Site

Plano, Texas, 75093, United States

TERMINATED

Related Links

• Related Info

MeSH Terms

Conditions

Phobia, Social; Psychological Well-Being; Phobic Disorders; Mental Disorders

Condition Hierarchy (Ancestors)

Anxiety Disorders; Personal Satisfaction; Behavior

Central Study Contacts

Clinical Studies Vistagen Therapeutics, Inc.

CONTACT

650-577-3693; clinicalstudies@vistagen.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2025
• First Posted: February 5, 2025
• Study Start: January 9, 2025
• Primary Completion: April 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: February 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (9)